Dr. Sue Currie serves as Chief Operating Officer of Virion Therapeutics, LLC, where she and the Company continue to pursue a safe, convenient, accessible, and effective treatment for functional cure for chronic hepatitis B for the 300+ million persons affected by this disease. Virion’s platform technologies, and pipeline, offer a novel checkpoint modifier containing mechanism to help restore a patient’s own immune response against cancer and chronic infections. Virion’s Lead Clinical Program, VRON-0200, presented data earlier this year at APASL and EASL that many experts have commented have a high potential to change the HBV functional cure landscape with VRON-0200 as the backbone treatment for functional cure. More VRON-0200 data are expected to be presented this year. As a result of these promising data, a global Phase 2b study (“SPARK-B”) for HBV Functional Cure is in development.
In addition to her current activities, Sue has 20+ years of strategic, clinical, and scientific leadership, not only within biotechnology and different pharm companies, but also in Veterans Health Administration, academic, correctional health, and community care settings. Additionally, Sue has authored numerous pivotal scientific publications in immuno-oncology and infectious diseases and is a Biotech Leader in the field.